Teva Pharmaceutical Industries Limited (TEVA)
NYSE: TEVA · Real-Time Price · USD
22.09
+0.78 (3.66%)
Dec 20, 2024, 4:00 PM EST - Market closed
Teva Pharmaceutical Employees
Teva Pharmaceutical Industries had 37,851 employees as of December 31, 2023. The number of employees increased by 1,025 or 2.78% compared to the previous year.
Employees
37,851
Change (1Y)
1,025
Growth (1Y)
2.78%
Revenue / Employee
$443,106
Profits / Employee
-$25,336
Market Cap
25.06B
Employees Chart
Employees History
Date | Employees | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 37,851 | 1,025 | 2.78% |
Dec 31, 2022 | 36,826 | -711 | -1.89% |
Dec 31, 2021 | 37,537 | -2,679 | -6.66% |
Dec 31, 2020 | 40,216 | 177 | 0.44% |
Dec 31, 2019 | 40,039 | -2,496 | -5.87% |
Dec 31, 2018 | 42,535 | -9,257 | -17.87% |
Dec 31, 2017 | 51,792 | -5,168 | -9.07% |
Dec 31, 2016 | 56,960 | 14,072 | 32.81% |
Dec 31, 2015 | 42,888 | -121 | -0.28% |
Dec 31, 2014 | 43,009 | -1,936 | -4.31% |
Dec 31, 2013 | 44,945 | -1,003 | -2.18% |
Dec 31, 2012 | 45,948 | 194 | 0.42% |
Dec 31, 2011 | 45,754 | 6,094 | 15.37% |
Dec 31, 2010 | 39,660 | 4,571 | 13.03% |
Dec 31, 2009 | 35,089 | -3,218 | -8.40% |
Dec 31, 2008 | 38,307 | 10,395 | 37.24% |
Dec 31, 2007 | 27,912 | 1,242 | 4.66% |
Dec 31, 2006 | 26,670 | 11,972 | 81.45% |
Dec 31, 2005 | 14,698 | 885 | 6.41% |
Dec 31, 2004 | 13,813 | 2,853 | 26.03% |
Dec 31, 2003 | 10,960 | 1,383 | 14.44% |
Dec 31, 2002 | 9,577 | 591 | 6.58% |
Dec 31, 2001 | 8,986 | 361 | 4.19% |
Dec 31, 2000 | 8,625 | - | - |
Sources: Annual number of employees according to filings submitted to the U.S. Securities and Exchange Commission (SEC). Data is also manually gathered from company press releases, IPO filings, and other official sources.
Related Stocks
Company Name | Employees |
---|---|
Koninklijke Philips | 69,656 |
Humana | 67,600 |
Cardinal Health | 48,900 |
Mettler-Toledo International | 17,300 |
Illumina | 13,360 |
West Pharmaceutical Services | 10,600 |
DexCom | 9,600 |
Waters | 7,900 |
TEVA News
- 1 day ago - Teva to Host Conference Call to Discuss Fourth Quarter and Full Year 2024 Financial Results and 2025 Financial Guidance at 8 a.m. ET on January 29, 2025 - GlobeNewsWire
- 3 days ago - Teva Pharmaceutical Releases Impressive Phase 2 Candidate Data For Gastro-Related Diseases - Benzinga
- 3 days ago - TEVA stock soars 26%: What's going on with Teva Pharmaceuticals? - Invezz
- 4 days ago - Positive Test Results Reported for Teva-Sanofi Drug for Ulcerative Colitis, Crohn's - Investopedia
- 4 days ago - Teva Soars, Sanofi Gains on Strong Trial Results for IBD Treatment - WSJ
- 4 days ago - Why Are Teva And Sanofi Stocks Trading Higher On Tuesday? - Benzinga
- 4 days ago - Teva, Sanofi say drug to treat IBD met primary targets - Reuters
- 4 days ago - Teva and Sanofi Announce Duvakitug (Anti-TL1A) Positive Phase 2b Results Demonstrating Best-in-Class Potential in Ulcerative Colitis and Crohn's Disease - GlobeNewsWire